Bayer Pharma Aktiengesellschaft

Lead Discovery Center Gmbh

Matt Cotten

Wilfried Schwab

Zoltán Greff

Axel Choidas

Bert Klebl

Edmund Hoppe

Don Simpson

Klaus Godl

Gerhard Müller

Joelle Le

Doris Hafenbradl

Jackie Macritchie

Thomas Herget

Alexander Backes

Andrea Missio

Jose Bravo

Birgit Zech

Ola Engkvist

John Harris

Beatrice Felber

Vladimir Savic

Achim Freisleben

Brad Sherborne

Peter Habenberger

Christian Hartung

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

Growing community of inventors

Banjul, Gambia

Matt Cotten